LENZ
LENZ Therapeutics, Inc. Common Stock
stockNASDAQ
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company's platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients' lives
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.96 | 2026-09-28 | -9.60% | -4.192 |
| 1M | 5.96 | 2026-09-04 | -39.93% | 2.144 |
| 3M | 5.60 | 2026-07-06 | -36.07% | 0.529 |
| 6M | 9.61 | 2026-04-06 | -62.75% | 0.812 |
| 1Y | 48.74 | 2025-10-03 | -92.66% | 1.441 |
| 2Y | 25.78 | 2024-10-04 | -86.11% | — |
LENZ Therapeutics, Inc. Common Stock (NASDAQ:LENZ) stock price today is $3.58, and today's volume is 1,126,916. LENZ is down 5.541% today. The 30 day average volume is 722,005. LENZ market cap is $112.48M with 31.42M shares outstanding.